MEDINA, WA, February 11, 2026 /24-7PressRelease/ -- Bryce D. Carmine has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Mr. Carmine based in Medina, Washington, currently serves as a member of the board of directors at HaemaLogiX Ltd., a position he has held since 2024. In this capacity, he provides strategic oversight and guidance to the company, leveraging his expertise in the commercialization of new pharmaceutical products. Mr. Carmine is currently the chairman and non-executive director of Kazia Therapeutics Limited. Both companies are Australian based entities.

Mr. Carmine served as chairman and chief executive officer of HaemaLogiX Ltd. from 2015 until 2023. During his tenure, he played a leading role in shaping the company's vision and operational strategy, driving the strategic focus of the company. His leadership was important in positioning HaemaLogiX as an important contributor of new technology in the treatment of multiple myeloma a fatal blood cancer.

Between 2017 and 2024, Mr. Carmine served as a non-executive director at Kazia Therapeutics Limited in Sydney, Australia. He contributed to corporate governance and provided valuable insights into product development and market strategy, supporting the company's mission to advance oncology therapeutics.

Prior to his retirement in 2011 Mr. Carmine's distinguished career includes significant executive leadership roles at Eli Lilly and Company in Indianapolis, Indiana. From 2009 to 2011, he was executive vice president and president of Lilly Bio-Medicines, overseeing global operations for one of the company's largest business units. Before this role, from 2008 to 2009, he served as executive vice president of international marketing and sales, where he directed worldwide commercial strategies for Eli Lilly's portfolio.

From 2000 to 2008, Mr. Carmine was president of global product development at Eli Lilly and Company. In this capacity, he managed cross-functional teams responsible for the late phase development of novel therapies.

A defining chapter in Mr. Carmine's professional journey was his leadership of Eli Lilly's Japan operations. As president and general manager from 1995 to 1999 and previously as managing director of Eli Lilly Australia & New Zealand, from 1989 to 1995 based in Sydney, Australia. His most notable achievement during this period was managing Japan operations—recognized as the world's second-largest pharmaceutical market—and guiding them through transformative regulatory changes that affected the entire industry. By identifying early opportunities presented by Japanese regulatory reforms, Mr. Carmine over multiple years of continuous support from 1995 to 2011 enabled near-simultaneous drug development alongside United States operations rather than following the costly separate processes required prior to this time in Japan. Under his stewardship, the Japanese business expanded from several hundred million dollars to major contributor of growth for the company. This was a critical accomplishment that offset losses from key United States patent expirations and added meaningfully to the corporate financial health.

His academic background laid a strong foundation for his career achievements. Mr. Carmine earned a Bachelor of Science degree in biochemistry, with minors in microbiology and genetics from Massey University in New Zealand in 1974. This scientific training equipped him with the analytical skills essential for navigating complex challenges within pharmaceutical development and commercialization.

Mr. Carmine attributes his success to a strategic focus characterized by careful assessment and deliberate planning, qualities that have guided both his professional decisions and personal pursuits. He chose a career in pharmaceuticals because it aligned with his scientific interests while offering opportunities for meaningful impact through business innovation.

Beyond his professional commitments, Mr. Carmine has been active over the years supporting several educational organizations and is currently an advisor to the dean of environmental science and public policy at the University of Indiana in Bloomington, demonstrating an ongoing dedication to advancing science-driven solutions for societal benefit.

In his personal life, Mr. Carmine enjoys wine collecting, a pursuit that reflects his appreciation for craftsmanship and tradition. Looking ahead, he aims to focus on supporting HaemaLogiX Ltd. as they progress toward their next phase of development with aspirations for broader global development in the United States and beyond.

Mr. Carmine's career exemplifies visionary leadership grounded in the scientific expertise acquired through successful drug development, strategic acumen, and unwavering commitment to advancing healthcare innovation on a global scale.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #